natgillin/translations-raw huggingface dataset:
Injicer opløsningen subkutant i en vinkel på 45-90°. 
The solution should be injected subcutaneously, at 45-90° angle.
Almindelig Hævede øjne*, abnormt syn*, konjunctivitis* Ikke almindelig Øjenblødning*, øjenlågsinfektion*, chalazion blefaritis 
Eye swelling*, Vision abnormal*, Conjunctivitis* Uncommon Eye haemorrhage*, Eyelid infection*, Chalazion Blepharitis
Patienter, som oplever bortezomibrelaterede neuropatiske smerter og/eller perifer neuropati, skal behandles som angivet i tabel 1 (se pkt. 
Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in table 1 (see section 4.4).
Bortezomib bruges til behandling af myelomatose (kræft i knoglemarven) hos patienter over 18 år: - Alene eller sammen med lægemidlerne pegyleret liposomal doxorubicin eller dexamethason til patienter, hvis sygdom forværres (er progressiv) efter mindst én forudgående behandling, og som ikke har haft gavn af eller mulighed for at få en transplantation af blodstamceller (knoglemarvstransplantation). 
Bortezomib is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years: - alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
• At kravene til rekonstitution er forskellige ved intravenøs (i.v.) 
• different reconstitution requirements for intravenous (IV) or subcutaneous (SC) use
bakteriel), Epstein-Barr virusinfektion, herpes genitalis, tonsillitis, mastoiditis, postviralt træthedssyndrom 
Meningitis (inc bacterial), Epstein-Barr virus infection, Genital herpes, Tonsillitis, Mastoiditis, Post viral fatigue syndrome
De væsentligste effektresultater er vist i tabel 12. 
Main efficacy results are presented in table 12.
synstab eller -forstyrrelser og stakåndethed 
visual loss or disturbances and shortness of breath
HBV-infektion med dødelig udgang forekom hos 0,8 % (n=2) af patienterne i non-bortezomib-armen (rituximab, cyclophosphamid, doxorubicin, vincristin og prednison; R-CHOP) og hos 0,4 % (n=1) af patienterne i armen med bortezomib plus rituximab, cyclophosphamid, doxorubicin og prednison (BRCAP). 
HBV infection with fatal outcomes occurred in 0.8% (n=2) of patients in the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) and 0.4% (n=1) of patients receiving bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BR-CAP).
TTP = Tid til progression CI = konfidensinterval B = bortezomib ; Dex = dexamethason 
B=bortezomib; Dex=dexamethasone
Du kan opleve et fald i antallet af: - Blodplader, hvilket kan gøre dig mere tilbøjelig til at få blå mærker eller til at bløde uden påviselig skade (f.eks. blødning fra tarmene, maven, munden og gummerne, blødning i hjernen eller blødning fra leveren). 
You may experience a reduction in the number of: - platelets, which may make you be more prone to bruising, or to bleeding without obvious injury (e.g., bleeding from your bowels, stomach, mouth and gum or bleeding in the brain or bleeding from the liver) - red blood cells, which can cause anaemia, with symptoms such as tiredness and paleness - white blood cells may make you more prone to infections or flu-like symptoms.
Bortezomib vil blive givet af sundhedspersonale, som har erfaring med behandling med cytostatika. 
Bortezomib will be administered by a health care professional experienced in the use of cytotoxic medicines.
Cytotoksisk. 
Cytotoxic
Testikelsygdom*, prostatitis, sygdom i mammae hos kvinder, epididymal ømhed, epididymitis, bækkensmerter, sårdannelse på vulva 
Testicular disorder*, Prostatitis, Breast disorder female, Epididymal tenderness, Epididymitis, Pelvic pain, Vulval ulceration
De almindeligste bivirkninger, der er indberettet under behandling med bortezomib, er kvalme, diarré, forstoppelse, opkastning, træthed, feber, trombocytopeni, anæmi, neutropeni, perifer neuropati (inklusive sensorisk neuropati), hovedpine, paræstesier, nedsat appetit, dyspnø, udslæt, herpes zoster og myalgi. 
The most commonly reported adverse reactions during treatment with bortezomib are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.
• Ændringer af leverfunktionen 
• Alteration of liver function
Tabel 4: Dosering for bortezomib kombinationsbehandling til patienter med tidligere ubehandlet myelomatose, som er egnet til hæmatopoietisk stamcelletransplantation 
Table 4: Posology for bortezomib combination therapy for patients with previously untreated multiple myeloma eligible for haematopoietic stem cell transplantation
Almindelig Hypertension*, hypotension*, ortostatisk hypotension 
Hypertension*, Hypotension*, Orthostatic
105 (81 %) og 78 (61 %) patienter i henholdsvis BTDx og TDx-gruppen fik en enkelt autolog stamcelletransplantation. 
One single autologous stem cell transplant was received by 105 (81%) patients and 78 (61%) patients in the BTDx and TDx groups, respectively.
Perifer emboli, lymfødem, bleghed, erytromelalgi, vasodilatation, misfarvning af vener, veneinsufficiens 
Peripheral embolism, Lymphoedema, Pallor, Erythromelalgia, Vasodilatation, Vein discolouration, Venous insufficiency
CI = konfidensinterval; CR = komplet respons; nCR = næsten komplet respons; ITT = intent to treat; RR = responsrate; B = bortezomib; BDx = bortezomib, dexamethason; VDDx = vincristin, doxorubicin, dexamethason; VGPR = virkeligt godt partielt respons; PR = partielt respons; OR = odds ratio; * Primært effektmål a 
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; B=bortezomib; BDx=bortezomib, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio.
Skyl det intravenøse kateter igennem med steril natriumchlorid 9 mg/ml (0,9 %) injektionsvæske. 
- Flush the peripheral or intravenous catheter with sterile, sodium chloride 9 mg/ml (0.9%) solution.
• Problemer med blodets størkning 
• Problems with blood clotting
Når bortezomib gives sammen med pegyleret liposomal doxorubicin, får du bortezomib intravenøst eller subkutant i en 21-dages behandlingscyklus, og pegyleret liposomal doxorubicin gives i en dosis på 30 mg/m på dag 4 i den 21-dages behandlingscyklus med bortezomib som en intravenøs infusion efter bortezomib-injektionen. 
When bortezomib is given together with pegylated liposomal doxorubicin, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m is given on day 4 of the bortezomib 21-day treatment cycle as an intravenous infusion after the bortezomib injection.
Hver pakning indeholder et hætteglas til engangsbrug. 
The vial is placed in a tray with a lid. Each pack contains 1 single-use vial.
Et lægemiddelinteraktionsstudie til vurdering af effekten af ketoconazol, en potent CYP3A-inhibitor, på bortezomibs farmakokinetik (som intravenøs injektion) viste en gennemsnitlig stigning i AUC for bortezomib på 35 % (CI90 % [1,032 til 1,772]) baseret på data fra 12 patienter. 
A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 35% (CI90% [1.032 to 1.772]) based on data from 12 patients.
- Sammen med lægemidlerne melphalan og prednison til behandling af patienter, der ikke tidligere er blevet behandlet for sygdommen, og som ikke er egnede til højdosiskemoterapi med transplantation af blodstamceller. 
- in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation.
kardiogent chok) 
Cardiac disorders
• At kravene til rekonstitution af bortezomib 3,5 mg er forskellige ved i.v. 
• different reconstitution requirements for bortezomib 3.5 mg IV or SC use
• Graf over induktionstransplantationsregimer 
• Induction Transplant Regimens Graph.
Blæreirritation Ikke almindelig Vaginalblødning, genitale smerter*, erektil dysfunktion 
Uncommon Vaginal haemorrhage, Genital pain*, Erectile dysfunction,
Tid til næste behandling Hændelser n (%) Median a 
Time to next therapy Events n (%) Median a
Malign tumor, leukaemia plasmacytica, nyrecellekarcinom, masse (benign cyste), mycosis fungoides, godartet tumor* 
Neoplasm malignant, Leukaemia plasmacytic, Renal cell carcinoma, Mass, Mycosis fungoides, Neoplasm benign*
Blødning i øret, vestibulær neuronitis, uspecificeret øresygdom 
Ear haemorrhage, Vestibular neuronitis, Ear disorder NOS
Alle grader PN ≥ Grad 2 PN ≥ Grad 3 PN Seponering grundet PN (%) VDDx=vincristin, doxorubicin, dexamethason; BDx= bortezomib, dexamethason; TDx=thalidomid, dexamethason; BTDx= bortezomib, thalidomid, dexamethason; PN=perifer neuropati Bemærk: Perifer neuropati inkluderede de ”foretrukne termer”: perifer neuropati, perifer motorisk neuropati, perifer sensorisk neuropati og polyneuropati. 
VDDx=vincristine, doxorubicin, dexamethasone; BDx=bortezomib, dexamethasone; TDx=thalidomide, dexamethasone; BTDx=bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.
Farmakoterapeutisk klassifikation: Antineoplastiske midler, andre antineoplastiske midler, ATC-kode: 
Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX32.
Når bortezomib gives alene, vil du få 4 doser bortezomib intravenøst eller subkutant på dag 1, dag 4, dag 8 og dag 11 efterfulgt af en pause på 10 dage uden behandling. 
When bortezomib is given alone, you will receive 4 doses of bortezomib intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a 10-day ‘rest period' without treatment.
n=127 (ITT population) 
N=130 (ITT population) N=127 (ITT population)
• Lidelser forbundet med injektionsstedet eller -udstyret 
• Injection site or injection device related disorders
Patienterne i BR-CAP-armen fik bortezomib (1,3 mg/m på dag 1, 4, 8, 11, hvileperiode dag 12-21), rituximab 
Patients in the BR-CAP treatment arm received bortezomib (1.3 mg/m2; on days 1, 4, 8, 11, rest period days
Alvorlige "ikke almindelige" bivirkninger, der er indberettet under behandling med bortezomib, inkluderer hjerteinsufficiens, tumorlysesyndrom, pulmonal hypertension, posteriort reversibelt encefalopatisyndrom samt akutte, diffuse, infiltrative lungesygdomme. 
Serious adverse reactions uncommonly reported during treatment with bortezomib include cardiac failure, tumour lysis syndrome, pulmonary hypertension, posterior reversible encephalopathy syndrome, acute diffuse infiltrative pulmonary disorders and rarely autonomic neuropathy.
Denne 3-ugers periode betragtes som en behandlingscyklus. 
This 3-week period is considered a treatment cycle.
Hvis der opstår lokale reaktioner på injektionsstedet efter en subkutan injektion af bortezomib, bør bortezomib enten gives i en lavere koncentration (Bortezomib Fresenius Kabi 3,5 mg rekonstitueres til 1 mg/ml i stedet for 2,5 mg/ml), eller det anbefales at skifte til intravenøs injektion. 
If local injection site reactions occur following bortezomib subcutaneous injection, either a less concentrated bortezomib solution (bortezomib 3.5 mg to be reconstituted to 1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
Alle grader PN ≥ Grad 2 PN ≥ Grad 3 PN Seponering grundet PN (%) BR-CAP= Bortezomib, rituximab, cyclophosphamid, doxorubicin og prednison; R-CHOP=Rituximab, cyclophosphamid, doxorubicin, vincristin og prednison; PN=perifer neuropati Perifer neuropati inkluderede de ”foretrukne termer”: perifer sensorisk neuropati, perifer neuropati, perifer motorisk neuropati og perifer sensomotorisk neuropati 
BR-CAP=bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy
Bortezomib benyttes til behandling af mantle-celle-lymfom (en type kræft, som påvirker lymfeknuderne) i kombination med lægemidlerne rituximab, cyclophosphamid, doxorubicin og prednison, hos patienter på 18 år og derover, hvis sygdom ikke tidligere er blevet behandlet, og som ikke er egnede til at gennemgå en transplantation af blodstamceller. 
Bortezomib is used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable.
I tilfælde af lokale reaktioner på injektionsstedet efter en subkutan injektion af bortezomib anbefales det enten at administrere en mindre koncentreret bortezomib opløsning (1 mg/ml i stedet for 2,5 mg/ml) subkutant eller skifte til intravenøs administration. 
• If local injection site reactions occur following bortezomib injection subcutaneously, either a less concentrated bortezomib solution (1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
Du må ikke køre bil, motorcykel eller cykle eller arbejde med værktøj eller maskiner, hvis du oplever disse bivirkninger. 
Do not drive or operate tools or machines if you experience such side effects; even if you do not, you must still be cautious.
• Tidligere er besvimet, har været svimmel eller ør i hovedet 
• fainting, dizziness or light-headedness in the past
Bortezomib som monoterapi eller i kombination med pegyleret liposomal doxorubicin eller dexamethason er indiceret til behandling af voksne patienter med progressiv myelomatose, som tidligere har fået mindst én behandling, og som allerede har gennemgået eller er uegnede til hæmatopoietisk stamcelletransplantation. 
Bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.
Respirationssvigt, akut respiratory distress syndrome, apnø, pneumothorax, atelektase, pulmonal hypertension, hæmoptysis, hyperventilation, ortopnø, pneumonitis, respiratorisk alkalose, takypnø, lungefibrose, bronkiesygdom*, hypokapni*, interstitiel lungesygdom, lungeinfiltration, sammensnøring af halsen, tør i halsen, øget sekret i de øvre luftveje, halsirritation, øvre luftvej-hoste-syndrom 
Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat, Increased upper airway secretion, Throat irritation, Upper-airway cough syndrome
Patienter, som er egnede til stamcelletransplantation Der blev gennemført to randomiserede, open-label, multicenter fase III-studier (IFM-2005-01, MMY3010), for at bestemme sikkerheden og effekten af bortezomib i dobbel- og tripel-kombination med andre kemoterapeutika som induktionsterapi forud for stamcelletransplantation hos patienter med tidligere ubehandlet myelomatose. 
Two randomised, open-label, multicenter Phase III trials (IFM-2005-01, MMY-3010) were conducted to demonstrate the safety and efficacy of bortezomib in dual and triple combinations with other chemotherapeutic agents, as induction therapy prior to stem cell transplantation in patients with previously untreated multiple myeloma.
• Betændelse i hjertesækken eller væsken omkring hjertet 
• Inflammation of the lining around your heart or fluid around your heart
• Helvedesild (lokaliseret, herunder omkring øjnene eller spredt over kroppen) 
• Shingles (localized including around the eyes or spread across the body)
• Infektioner inklusive lungebetændelse, luftvejsinfektioner, bronkitis, svampeinfektioner, hoste med slim, influenzalignende sygdom 
• Infections, including pneumonia, respiratory infections, bronchitis, fungal infections,
• Infektion eller inflammation (betændelseslignende tilstand) i mave og/eller tarme 
• Infection or inflammation of the stomach and intestine
Akut intervention med positive inotropiske- eller pressormidler påvirkede faldet i hjertekontraktilitet og hypotension hos hunde. 
In dogs, the decreased cardiac contractility and hypotension responded to acute intervention with positive inotropic or pressor agents.
Tabel 9: Forekomst af perifer neuropati under induktionsbehandling ved toksicitet og seponering på grund af perifer neuropati 
Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment discontinuation due to peripheral neuropathy IFM-2005-01
For efterfølgende doser lå den gennemsnitlige totale clearance på 15-32 l/t og 18-32 l/t for doser på henholdsvis 1,0 mg/m og 1,3 mg/m 
Mean total body clearances were 102 and 112 l/h following the first dose for doses of 1.0 mg/m and 1.3 mg/m2, respectively, and ranged from 15 to 32 l/h and 18 to 32 l/h following subsequent doses for doses of 1.0 mg/m and 1.3 mg/m 2, respectively.
Ikke almindelig Almen fysisk helbredsforringelse*, ansigtsødem*, reaktion på injektionsstedet*, slimhindegener*, smerter i brystet, gangforstyrrelser, kuldefornemmelse, ekstravasation*, kateterrelaterede komplikationer*, forandringer i væskebehov*, trykken for brystet, fornemmelse af ændret legemstemperatur*, smerter på injektionsstedet* 
Uncommon General physical health deterioration*, Face oedema*, Injection site reaction*, Mucosal disorder*, Chest pain, Gait disturbance, Feeling cold, Extravasation*, Catheter related complication*, Change in thirst*, Chest discomfort, Feeling of body temperature change*, Injection site pain*
Sådan skal du bruge Bortezomib Fresenius Kabi 
How to use Bortezomib Fresenius Kabi
, cyclophosphamid 750 mg/m og doxorubicin 50 mg/m 2. 
Rituximab at 375 mg/m2, cyclophosphamide at 750 mg/m and doxorubicin at 50 mg/m
De bivirkninger, du kan opleve, hvis du får bortezomib sammen med andre lægemidler til behandling af mantle-celle-lymfom, er angivet nedenfor: 
If you are given bortezomib together with other medicines for the treatment of mantle cell lymphoma the side effects you may get are listed below:
-- Pause - 
-- -- -- -- rest period
Tabel 6: Anbefalede initiale dosisjusteringer for bortezomib til patienter med nedsat leverfunktion. 
Table 6: Recommended starting dose modification for bortezomib in patients with hepatic impairment
Følgende lægemidler administreres som intravenøs infusion på dag 1 i hver 3-ugers behandlingscyklus med bortezomib: rituximab 375 mg/m2, cyclophosphamid 750 mg/m og doxorubicin 50 mg/m 
The following medicinal products are administered on day 1 of each bortezomib 3 week treatment cycle as intravenous infusions: rituximab at 375 mg/m2, cyclophosphamide at 750 mg/m and doxorubicin at 50 mg/m Prednisone is administered orally at 100 mg/m on days 1, 2, 3, 4 and 5 of each bortezomib treatment cycle.
#, uspecificeret blodsygdom, hæmoragisk diatese, lymfocytinfiltration 
#, Blood disorder NOS, Haemorrhagic diathesis, Lymphocytic infiltration
CR-raten hos førstetilbagefald, T-celle ALL patienter (n=22) var 68 % (95 % CI: 45, 86) og den 4-mdr. 
The CR rate in first-relapsed T-cell ALL patients (n=22) was 68% (95% CI: 45, 86) and the 4-month event free survival rate was 67% (95% CI: 42, 83).
• At eventuelle bivirkninger eller fejlmedicinering i forbindelse med administration af bortezomib 
• to report any adverse event, or medication error experienced with the administration of bortezomib 3.5 mg.
I cyklus 1-4 indgives bortezomib to gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32. 
In cycles 1-4, bortezomib is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
Bortezomib kombineret med rituximab, cyclophosphamid, doxorubicin og prednison er indiceret til behandling af voksne patienter med tidligere ubehandlet mantle-celle-lymfom, som ikke er egnede til hæmatopoietisk stamcelletransplantation. 
Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Det skal du vide, før du begynder at bruge Bortezomib Fresenius Kabi 
What you need to know before you use Bortezomib Fresenius Kabi
#, øjeninflammation*, diplopi, øjentørhed*, øjenirritation*, øjensmerter, øget tåreflåd, øjenflåd 
#, Eye inflammation*, Diplopia, Dry eye*, Eye irritation*, Eye pain, Lacrimation increased, Eye discharge
I et lægemiddelinteraktionsstudie til vurdering af effekten af rifampicin, som er en potent CYP3A4induktor, på bortezomibs farmakokinetik (som intravenøs injektion) sås en gennemsnitlig reduktion af AUC for bortezomib på 45 % baseret på data fra 6 patienter. 
A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC reduction of 45% based on data from 6 patients.
Behandlingen med bortezomib skal påbegyndes under tilsyn af en kvalificeret læge med erfaring inden for behandling af cancerpatienter. 
Bortezomib treatment must be initiated under supervision of a physician experienced in the treatment of cancer patients, however bortezomib may be administered by a healthcare professional experienced in use of chemotherapeutic agents.
Batch 
BATCH NUMBER
Et lægemiddelinteraktionsstudie til vurdering af effekten af omeprazol, en potent CYP2C19-inhibitor, på bortezomibs farmakokinetik (som intravenøs injektion) viste ingen signifikant effekt på bortezomibs farmakokinetik baseret på data fra 17 patienter. 
In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 17 patients.
*RR (Post-induktion) *CR+nCR 
*RR (Post-induction) CR+nCR
#, dermatitis*, hårsygdom*, petekkier, ekkymose, hudlæsion, purpura, udfyldning i huden*, psoriasis, hyperhidrose, nattesved, decubitus 
#, Stevens-Johnson syndrome Dermatitis*, Hair disorder*, Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*, Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer
Et lægemiddelinteraktionsstudie til vurdering af effekten af melphalan-prednison på bortezomibs farmakokinetik (som intravenøs injektion) viste en gennemsnitlig stigning i AUC for bortezomib på 17 % baseret på data fra 21 patienter. 
A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data from 21 patients.
Muskoskeletale smerter* 
Very common Musculoskeletal pain* Common
De bivirkninger, du kan opleve, hvis du får bortezomib til behandling af myelomatose, er angivet nedenfor: 
If you are given bortezomib for the treatment of multiple myeloma the side effects you may get are listed below: